DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
Brief description of study
If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main goal of this study is to test the effects of the study drugs ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.
Clinical Study Identifier: s18-00026
ClinicalTrials.gov Identifier: NCT02834013
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
